1. INTRODUCTION

One of the major obstacles in developing new drugs today is that many active pharmaceutical ingredients (APIs) do not dissolve well in water. This is especially true for newer chemical compounds created through high-throughput screening, which often have complex structures. A large number of these compounds fall into Biopharmaceutics Classification System (BCS) Class II and IV, meaning they have low solubility and, in some cases, poor permeability. These properties can lead to poor absorption in the body, limiting the clinical effectiveness of otherwise promising drugs. To solve this problem, researchers have explored converting drugs from their crystalline to amorphous form. Unlike crystalline materials that have an organized, stable structure, amorphous forms are disordered and have higher energy. This gives them improved solubility and faster dissolution rates, which may lead to better absorption in the gastrointestinal tract. However, the unstable nature of amorphous drugs also makes them more likely to revert to the crystalline form during storage or use, which can reduce their effectiveness and shelf life¹.

To improve stability, several formulation strategies have been developed. These include techniques such as creating amorphous solid dispersions (ASDs), forming co-amorphous mixtures, and using advanced processes like spray drying and hot-melt extrusion. These approaches help maintain the amorphous state and improve the drug’s performance. Along with formulation, it is equally important to use effective characterization methods to confirm the drug’s amorphous nature, detect any phase changes, and predict long-term stability².

This review aims to give a complete overview of these approaches. It begins with the basic principles and benefits of using amorphous systems, followed by a detailed explanation of formulation strategies and the reasoning behind selecting certain excipients.

The performance of solid dispersions is strongly influenced by the uniform distribution of the drug within the carrier matrix. Variations in stability and dissolution behavior depend on whether the drug exists in a crystalline or amorphous state. Despite this, limited studies have distinguished between amorphous drug particles and molecularly dispersed forms. Techniques such as Confocal Raman Spectroscopy are useful for evaluating homogeneity, while FTIR provides insight into drug–matrix interactions. Temperature Modulated Differential Scanning Calorimetry (TMDSC), offering higher sensitivity than conventional DSC, allows for the assessment of drug mixing and the quantification of the molecularly dispersed fraction by separating reversible and irreversible thermal events ^2.

2. Fundamentals of Amorphous Drug Systems:

Amorphous drug systems are solid forms of medicines in which the molecules do not follow a regular, repeating pattern. This lack of long-range molecular order sets them apart from crystalline forms, where the molecules are arranged in a well-organized lattice. While the crystalline structure offers greater thermodynamic stability, it often limits how well a drug can dissolve. On the other hand, the amorphous form is a high-energy, disordered state comparable to a super cooled liquid that has solidified without forming a crystal. This irregular arrangement gives amorphous drugs unique physical and chemical properties, which are especially useful for enhancing the solubility and absorption of drugs that are poorly soluble in water (in Figure 1)^3.

Figure 1: Amorphous vs crystalline structure

2.1 Thermodynamic and Kinetic Properties:

Amorphous drug substances exist in a metastable state, meaning they are less thermodynamically stable than their crystalline counterparts. Because of their higher Gibbs free energy, these forms often show greater apparent solubility and dissolve more quickly in biological fluids. This can significantly improve the drug's absorption in the body. However, the lack of structural stability also makes amorphous drugs more sensitive to environmental conditions. They can easily undergo physical changes, such as recrystallization, especially when exposed to heat, humidity, or mechanical stress^4. As a result, developing stable amorphous formulations requires careful selection of excipients and processing methods that can prevent such transitions and preserve the drug’s performance throughout its shelf life.

2.2 Glass Transition Temperature (Tg):

One of the key characteristics of amorphous solids is the glass transition temperature (Tg). This is the temperature range at which the material changes from a hard, glass-like state to a softer, rubbery form. When stored below Tg, the movement of molecules is greatly limited, which helps maintain the physical stability of the formulation. However, if the storage temperature comes close to or exceeds Tg, molecular mobility increases, making the system more prone to crystallization. To prevent this, it is essential to use polymers or stabilizers with high Tg values, as they help keep the formulation in a stable amorphous state throughout its shelf life.⁵

2.3 Molecular Mobility and Relaxation:

In the amorphous phase, molecular mobility is a key determinant of stability. Even below Tg, residual mobility can allow for molecular rearrangement over time, leading to gradual relaxation toward a more thermodynamically favorable crystalline form. This phenomenon, known as physical aging, can influence not only stability but also mechanical and dissolution properties. Understanding and controlling relaxation dynamics is vital, particularly in long-term storage conditions.

2.4 Solubility and Supersaturation:

A major benefit of amorphous drug systems is their ability to generate and sustain a supersaturated state when dissolved in the gastrointestinal tract. This supersaturation increases the concentration gradient across the intestinal membrane, which can significantly enhance drug absorption. However, this condition is thermodynamically unstable, and the drug may begin to precipitate back into its crystalline form. To counter this, formulation approaches often include the use of polymeric precipitation inhibitors that help maintain supersaturation for a longer period, thereby improving the drug’s oral bioavailability.^6.

2.5 Factors Affecting Stability:

Several factors can influence the stability of amorphous drug systems, including:

· Moisture uptake, which can plasticize the system and reduce Tg.

· Temperature fluctuations, especially near or above Tg.

· Drug-excipient interactions, which may either stabilize or destabilize the system.

· Molecular weight and mobility of excipients.

3. Rationale for Amorphization:

The conversion of crystalline drugs into their amorphous forms is driven by the critical need to overcome solubility-related limitations that hinder the therapeutic efficacy of many modern drug candidates. A large proportion of newly developed active pharmaceutical ingredients (APIs) exhibit poor aqueous solubility, a characteristic that directly impacts dissolution rate and systemic absorption especially in orally administered formulations. Amorphization offers a scientifically validated approach to address these challenges by leveraging the inherent thermodynamic and kinetic advantages of the amorphous state.

3.1 Enhancing Apparent Solubility and Dissolution Rate:

Crystalline drugs tend to dissolve slowly because their tightly packed, orderly molecular structure requires a considerable amount of energy to break apart into individual molecules in solution. In contrast, amorphous forms lack this structural order, so they require much less energy to dissolve. As a result, they typically show much higher apparent solubilitysometimes several times greater than their crystalline counterparts. Furthermore, amorphous drugs dissolve more quickly, producing a sharp concentration gradient across biological membranes, which can significantly enhance drug absorption.⁷

3.2 Improving Bioavailability of BCS Class II and IV Drugs:

In the Biopharmaceutics Classification System (BCS), drugs in Class II (low solubility, high permeability) and Class IV (low solubility, low permeability) are often limited by how quickly they dissolve. For BCS Class II drugs, the main challenge is not permeability but poor solubility. Therefore, improving solubility and dissolution through amorphous formulations can lead to a direct improvement in oral bioavailability. This makes amorphization a particularly useful strategy during early stages of drug development and formulation screening.⁹

3.3 Supersaturation and Absorption Window Extension:

Amorphous drugs are capable of creating and sustaining a supersaturated state in the gastrointestinal environment. Supersaturation enhances the driving force for membrane permeation and can extend the absorption window, particularly for drugs with site-specific absorption. However, the challenge lies in maintaining this state long enough to allow for optimal absorption before the drug precipitates into a less bioavailable crystalline form.

3.4 Flexibility in Formulation Design:

Amorphous drug systems provide a flexible foundation for various formulation strategies, such as solid dispersions, co-amorphous mixtures, and nanoparticle-based amorphous forms. This adaptability enables formulators to design drug delivery systems tailored to specific needs, including controlled release, targeted delivery, or population-specific requirements like pediatric or geriatric patients. Moreover, the use of functional excipients can enhance the manufacturing process, improve the physical stability of the drug, and increase patient adherence by making the formulations more acceptable and easier to use¹⁰.

3.5 Opportunities for Lifecycle Management and Patent Extension:

From a commercial perspective, amorphous formulations also serve as a strategy for lifecycle management of existing drugs. Reformulating an old molecule into an amorphous system with improved performance can lead to new intellectual property, extending market exclusivity and adding value to the drug product portfolio.

4. Formulation Strategies:

Formulating a stable and effective amorphous drug product requires careful selection of processing techniques and excipients to prevent recrystallization and ensure consistent drug release. The primary objective is to maintain the drug in its disordered state throughout its shelf life while leveraging its enhanced solubility profile. A variety of formulation strategies have been developed to achieve this; each tailored to the physicochemical properties of the drug molecule and the desired product characteristics.

4.1 Amorphous Solid Dispersions (ASDs):

Amorphous solid dispersions (ASDs) are one of the most commonly used and successful approaches for formulating poorly soluble drugs in their amorphous form. In ASDs, the drug is distributed at the molecular level within a polymer matrix. This matrix plays several important roles: it helps keep the drug in its amorphous state, reduces the chance of recrystallization by restricting molecular movement, and improves dissolution by increasing the wettability of the drug particles¹¹.

Hydrophilic polymers frequently used in ASDs include hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), Soluplus®, and various types of Eudragit®. Several techniques are available for preparing ASDs. Spray drying is one of the most widely used methods and involves dissolving the drug and polymer in a solvent, followed by rapid drying to form fine amorphous particles. Hot-melt extrusion (HME) is another scalable technique where the drug and polymer are blended under heat and mechanical force to produce a uniform extrudate. Other methods, such as solvent evaporation using rotary evaporators or vacuum drying, also remove solvent to yield amorphous drug-polymer systems. The choice of polymer and manufacturing method plays a major role in determining key properties of the final product, including the glass transition temperature (Tg), physical stability, and the rate at which the drug is released¹².

4.2 Co-Amorphous Systems:

Co-amorphous systems offer a promising alternative to traditional polymer-based formulations by combining a drug with a low-molecular-weight co-former to form a single-phase amorphous structure. Unlike amorphous solid dispersions (ASDs), which depend on polymers for stabilization, co-amorphous systems achieve stability through strong molecular interactions such as hydrogen bonding, salt formation, or ionic interactions between the drug and the co-former^12. This strategy is especially appealing because it typically requires a lower amount of excipients and can potentially provide therapeutic effects from both components if the co-former is pharmacologically active.

Common co-formers used in these systems include amino acids like L-arginine and L-lysine, as well as small molecules such as citric acid and saccharin. These combinations not only improve solubility but also help maintain the drug in its amorphous state over time. Co-amorphous formulations are usually prepared by techniques like solvent evaporation or ball milling, both of which facilitate intimate mixing of the drug and co-former. Compared to pure amorphous drugs, co-amorphous systems generally show better physical stability and offer a viable option for drugs that are poorly compatible with polymer-based carriers¹³.

4.3 Cryogenic Milling and Ball Milling:

Mechanical techniques like cryogenic milling and high-energy ball milling are commonly used to induce amorphization in drug substances by physically disrupting their crystalline structure. These solvent-free methods are relatively simple and environmentally friendly, making them ideal for early-phase research and feasibility studies. Cryomilling is carried out at extremely low temperatures, which helps avoid thermal degradation, while ball milling relies on repeated collisions and friction to break down the crystal lattice and create a disordered, amorphous state.^14.

Although these techniques are effective in generating amorphous material, the resulting products often lack long-term stability. Without a stabilizing excipient, the drug is more prone to recrystallization during storage. To overcome this, additional processing such as incorporating the amorphous drug into a polymer matrix is usually needed to enhance stability. Despite this limitation, cryogenic and ball milling methods remain useful tools for quickly evaluating whether amorphization could improve the solubility and performance of a particular drug compound.

4.4 Supercritical Fluid Processing:

Supercritical fluid (SCF) processing is an advanced and environmentally friendly method for producing amorphous drug formulations. This technique commonly uses supercritical carbon dioxide (CO₂) as the processing medium to either dissolve or precipitate drugs under specific pressure and temperature conditions, resulting in the formation of fine amorphous particles with consistent shape and size ^15. One of the major advantages of SCF processing is that it avoids the use of harmful organic solvents and operates at relatively low temperatures, making it ideal for drugs that are sensitive to heat or solvents (in Figure 3).

Figure 2: Supercritical Fluid Processing

In addition to being a cleaner method, SCF technology allows for precise control over particle size, surface area, and porosity factors that can be optimized to improve drug dissolution and enhance bioavailability. However, despite these benefits, the high cost of equipment and the complexity of operation can limit its routine application in pharmaceutical manufacturing. Nevertheless, SCF processing remains a promising and sustainable alternative to traditional amorphization methods, especially for challenging drug candidates.

4.5 Freeze Drying and Antisolvent Precipitation:

Freeze drying (lyophilization) and antisolvent precipitation are mild processing methods often used for formulating heat-sensitive or unstable drugs. In freeze drying, the drug is first dissolved or suspended in a suitable solvent, then frozen, and finally dried under vacuum through sublimation. This results in a porous, amorphous solid with minimal thermal stress, making it especially useful for injectable drugs and biological products. Antisolvent precipitation works differently: it involves adding the drug solution to a nonsolvent typically water or alcohol in which the drug has low solubility. This leads to rapid precipitation of the drug in an amorphous form. Both methods are capable of producing particles with a high surface area and small size, often in the micro- or nanoscale range, which can significantly improve dissolution rates. However, to maintain the amorphous state during storage, the addition of stabilizers or polymers is usually required.

4.6 Emerging Formulation Approaches:

Recent advancements in pharmaceutical technology have led to innovative formulation strategies that combine amorphization with cutting-edge manufacturing techniques. One such approach is the development of nano-amorphous formulations, which merge particle size reduction with amorphous conversion to improve both dissolution rate and physical stability of poorly soluble drugs^16. Another promising technology is 3D printing, which enables the production of personalized amorphous dosage forms. This method offers precise control over drug dose, release profile, and tablet design, making it highly suitable for patient-specific therapies.

In addition, continuous manufacturing is gaining traction as a scalable and efficient method for producing amorphous formulations. This process allows for real-time quality monitoring and improved consistency, aligning well with regulatory expectations and the principles of Quality by Design (QbD)¹⁷. Together, these emerging technologies have the potential to significantly enhance drug performance and patient outcomes when combined with predictive modeling and rational formulation design.

5. Characterization Techniques:

Thorough characterization of amorphous drug systems is essential for confirming the successful transformation from a crystalline to an amorphous state, assessing stability, and predicting performance. Since amorphous forms lack the long-range molecular order of crystals, specialized techniques are required to evaluate their structural, thermal, morphological, and functional properties. The following tools are widely used in research and formulation development.

5.1 X-ray Powder Diffraction (XRPD):

X-ray Powder Diffraction (XRPD) is one of the most widely used and reliable techniques for distinguishing between crystalline and amorphous materials. Crystalline substances show sharp and distinct peaks in their diffraction patterns due to their well-organized, long-range molecular arrangement. In contrast, amorphous solids produce broad, diffuse halo patterns, reflecting their lack of structural order. XRPD is especially valuable for confirming whether a drug has been fully converted into the amorphous form after processing. It is also sensitive enough to detect small amounts of remaining crystallinity. Additionally, this method plays a key role in assessing the physical stability of formulations by identifying any recrystallization that may occur during storage^18.

5.2 Differential Scanning Calorimetry (DSC):

Differential Scanning Calorimetry (DSC) is a commonly used thermal analysis technique that helps evaluate key physical transitions in pharmaceutical materials, such as melting points and glass transition temperatures (Tg). Crystalline drugs typically show a sharp melting peak, while amorphous systems display a Tg, often without any melting signal. The Tg is especially important because it provides insight into the thermal behavior, molecular mobility, and overall stability of the amorphous phase. A Tg that is well above the storage temperature is generally considered favorable for maintaining physical stability. DSC can also be used to identify signs of recrystallization or polymorphic changes, making it a valuable tool for characterizing the thermal properties of amorphous drug formulations²⁰.

5.3 Thermogravimetric Analysis (TGA):

Thermogravimetric Analysis is used to determine changes in the weight of a sample as it is heated, providing insights into moisture content, thermal degradation, and volatility of components. In the context of amorphous drug systems, TGA is especially valuable for assessing the hygroscopic nature of a formulation. Moisture uptake can lower Tg and accelerate recrystallization, thus compromising stability. TGA data help formulators select proper packaging, storage conditions, and excipients to mitigate these risks.

5.4 Fourier Transform Infrared Spectroscopy (FTIR):

Fourier Transform Infrared (FTIR) spectroscopy is a valuable tool for detecting molecular interactions between drugs and excipients, such as hydrogen bonding or salt formation. When these interactions occur, they often cause noticeable shifts or changes in the characteristic absorption bands of the involved functional groups. These changes help confirm that strong interactions are present, which can stabilize the drug in its amorphous form. In both amorphous solid dispersions (ASDs) and co-amorphous systems, FTIR is especially useful for evaluating the miscibility between the drug and carrier, as well as for confirming the formation of a uniform amorphous phase. While primarily qualitative, FTIR can also provide semi-quantitative insights into the structural environment of the formulation components²¹.

5.5 Solid-State Nuclear Magnetic Resonance (ssNMR):

Solid-state NMR is a powerful analytical technique that offers atomic-level information about the molecular structure and dynamics of amorphous materials. Unlike traditional solution NMR, ssNMR can be used for non-soluble or disordered systems, making it ideal for characterizing amorphous solids. It helps detect subtle changes in chemical environments and can differentiate between amorphous and crystalline components in mixed systems. Although resource-intensive, ssNMR is often used in advanced research and for regulatory submissions requiring in-depth structural validation.

5.6 Scanning Electron Microscopy (SEM):

Scanning Electron Microscopy (SEM) is a powerful surface imaging technique used to examine the external structure, shape, and texture of particles. Although SEM does not directly confirm whether a material is amorphous, it is helpful in visually distinguishing between crystalline and amorphous forms. Crystalline particles often appear smooth and faceted, reflecting their orderly molecular arrangement, while amorphous materials typically show irregular, rough, or porous surfaces. SEM is also useful for detecting changes in particle morphology or aggregation that may occur due to different formulation techniques or processing conditions.^22.

5.7 In Vitro Dissolution and Supersaturation Testing:

In vitro dissolution testing is a critical tool for evaluating the performance of amorphous formulations. Enhanced dissolution rates are a primary goal of amorphization, and this method quantitatively assesses how quickly and to what extent the drug dissolves in a simulated gastrointestinal environment. Supersaturation studies can also be conducted to understand how long the amorphous drug remains in a high-energy, dissolved state before precipitating. These tests are vital for establishing in vitro–in vivo correlations (IVIVC) and predicting bioavailability improvements.

6. Stability Considerations:

The enhanced solubility benefits of amorphous drug formulations come at the cost of reduced physical and chemical stability. Since amorphous systems are in a high-energy, non-equilibrium state, they are inherently prone to recrystallization, especially when exposed to environmental stressors such as temperature fluctuations, humidity, or mechanical stress. Ensuring long-term stability is, therefore, a major formulation challenge and a critical determinant of commercial viability.

6.1 Physical Stability and Recrystallization Risk:

Physical stability refers to the capacity of an amorphous drug to retain its non-crystalline, disordered molecular arrangement over time. Owing to their elevated Gibbs free energy, amorphous forms are thermodynamically unstable and tend to revert to their more stable crystalline state a phenomenon known as recrystallization. This process may occur spontaneously during storage or be triggered by external factors such as mechanical stress, leading to a reduction in solubility and compromising the intended enhancement in bioavailability. The likelihood of recrystallization is governed by multiple factors, including the drug’s molecular mobility, storage temperature, and the presence of nucleation sites that facilitate crystal growth. ^22.

6.2 Influence of Glass Transition Temperature (Tg):

Glass transition temperature (Tg) is a key parameter in predicting the physical stability of amorphous systems. Below Tg, molecular mobility is significantly restricted, reducing the likelihood of recrystallization. Ideally, the formulation should have a Tg at least 50°C above the intended storage temperature to ensure sufficient kinetic stability. Polymers with high Tg values are often used to elevate the overall Tg of the amorphous matrix, thereby enhancing stability.

6.3 Effect of Moisture and Hygroscopicity:

Moisture is one of the most critical factors influencing the stability of amorphous drugs. Water acts as a plasticizer, reducing the glass transition temperature (Tg) and enhancing molecular mobility, which accelerates the recrystallization process. Many amorphous drugs and their polymeric carriers are hygroscopic, meaning they readily absorb moisture from the environment, particularly under conditions of high relative humidity. This sensitivity necessitates strict control of humidity during manufacturing, packaging, and storage. Strategies to mitigate moisture-related instability include the use of moisture-protective excipients, desiccants, and moisture-resistant packaging systems^23.

6.4 Chemical Stability and Degradation Pathways:

In addition to physical instability, amorphous drugs can also be chemically less stable than their crystalline counterparts. The increased surface area, higher molecular mobility, and interaction with excipients or moisture can lead to degradation through pathways such as oxidation, hydrolysis, or Maillard reactions. Stabilizing the chemical structure may require antioxidants, buffer agents, or selecting excipients that do not chemically interact with the API.

6.5 Role of Excipients in Stabilization:

Excipients, particularly polymers and co-formers, play a crucial role in maintaining the stability of amorphous systems. Polymers such as HPMC, PVP, and Soluplus not only inhibit nucleation and crystal growth but also elevate Tg and reduce molecular mobility. Co-amorphous systems utilize synergistic molecular interactions between the drug and co-former to create a thermodynamically more stable amorphous matrix. The choice and concentration of excipients must be optimized based on the specific drug properties and desired release profile.

6.6 Packaging and Storage Conditions:

Appropriate packaging is essential to protect amorphous formulations from environmental stressors, particularly humidity and temperature. Packaging materials should provide adequate moisture barrier properties and may include aluminum blisters, high-density polyethylene (HDPE) containers, or laminated foil pouches. Storage conditions should maintain low relative humidity and avoid temperature fluctuations to preserve physical and chemical integrity over time. Stability studies under ICH conditions are required to validate shelf-life claims and ensure regulatory compliance.

7. Regulatory and Industrial Aspects:

The development and commercialization of amorphous drug products require careful consideration of both scientific and regulatory expectations. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recognize the value of amorphous formulations, particularly in improving the solubility and bioavailability of BCS Class II and IV drugs. However, their approval depends on the ability to demonstrate consistent quality, performance, and stability throughout the product's shelf life.

7.1 Quality by Design (QbD) and Process Understanding:

Regulatory frameworks increasingly emphasize the implementation of Quality by Design (QbD) principles in pharmaceutical development. QbD involves a systematic approach to understanding formulation variables, material attributes, and process parameters that influence product quality. For amorphous systems, this includes identifying critical quality attributes (CQAs) such as particle size, residual crystallinity, moisture content, and Tg. A robust design space, supported by risk assessment tools and experimental design, ensures consistent performance and facilitates regulatory approval.^24.

7.2 Analytical Validation and Regulatory Documentation:

Amorphous drug formulations must be supported by validated analytical methods that can accurately characterize the amorphous state and detect any physical or chemical degradation. Regulatory submissions require comprehensive documentation of manufacturing processes, stability data, excipient compatibility studies, and analytical validation. Specific attention is given to techniques like XRPD, DSC, and FTIR, which must be sensitive enough to detect minimal recrystallization. Incomplete or unclear characterization may delay approval or require additional studies.²⁵

7.3 Industrial Scale-Up and Manufacturing Challenges:

Scaling up amorphous formulations from laboratory to industrial production presents unique challenges. Techniques such as hot-melt extrusion and spray drying must be optimized for large-scale consistency while maintaining the desired amorphous properties. Uniform mixing, solvent removal efficiency, and temperature control are critical to ensure batch-to-batch reproducibility. Additionally, continuous manufacturing technologies are being increasingly adopted in industry to enhance process control and minimize variability.

7.4 Regulatory Expectations for Stability and Shelf Life:

Stability is a core concern for regulatory bodies when evaluating amorphous products. Long-term stability studies under ICH guidelines (e.g., 25°C/60% RH and 40°C/75% RH) are mandatory to establish shelf life. Any signs of recrystallization or degradation during these studies can impact product approval. Regulatory agencies expect companies to justify their packaging choices, propose appropriate storage conditions, and use stability-indicating methods to monitor product quality over time.

7.5 Intellectual Property and Lifecycle Management:

From an industrial viewpoint, amorphous formulations can serve as a strategy for patent extension and product lifecycle management. Reformulating an existing drug into a more bioavailable amorphous form can provide opportunities for new intellectual property (IP) filings. This not only protects the product in a competitive market but can also lead to improved patient compliance and therapeutic performance. However, the uniqueness of the formulation process, polymer selection, and stabilization strategy must be well documented to support IP claims.

8. Recent Advances and Future Prospects:

The field of amorphous drug formulation continues to evolve with the integration of cutting-edge technologies and deeper scientific understanding. Recent advances have focused on improving physical stability, optimizing drug release, and streamlining production processes. These innovations are not only enhancing formulation efficiency but also making it feasible to bring more poorly soluble drug candidates to market.

8.1 Integration of Machine Learning and Predictive Modeling:

One significant advancement is the incorporation of machine learning (ML) and computational modeling to predict the behavior of amorphous formulations. Algorithms can now forecast miscibility, recrystallization risk, and physical stability based on drug-polymer properties and formulation parameters. Such predictive tools reduce experimental workload and accelerate the development timeline. For example, software models based on Hansen solubility parameters or molecular dynamics simulations can pre-screen excipient compatibility, improving the success rate of formulation design.

8.2 Application of Novel Polymers and Excipients:

Researchers are also exploring new classes of polymers that provide superior stabilization and release control. Copolymers with tailored hydrophilic-hydrophobic balance, ionic polymers, and bioinspired excipients (e.g., silk fibroin, cyclodextrins) are showing promise in creating more stable and bioavailable amorphous systems. These novel carriers can not only improve physical properties but may also enhance permeability and taste masking, offering multifunctionality in a single formulation.

8.3 Case Study: Itraconazole and ASDs:

Itraconazole, a poorly water-soluble antifungal agent, serves as one of the most extensively studied examples of successful amorphous solid dispersion (ASD) development. The commercial formulation Sporanox® employs hydroxypropyl methylcellulose phthalate (HPMCP) in a spray-dried ASD system, leading to a marked improvement in oral bioavailability over its crystalline counterpart. This case exemplifies how strategic polymer selection and optimized processing techniques can effectively address solubility challenges and result in a physically stable, commercially viable amorphous formulation.²⁶

8.4 Case Study: Co-Amorphous Formulation of Indomethacin:

Another notable example is the co-amorphous formulation of indomethacin with arginine. This system, developed using ball milling, showed enhanced dissolution rate and maintained stability over several months. The drug and co-former form strong hydrogen bonds, preventing recrystallization and improving physical performance. The simplicity and effectiveness of this co-amorphous system highlight its potential as an alternative to polymer-based dispersions, particularly for APIs that are sensitive to heat or incompatible with certain polymers.

8.5 Advances in Continuous Manufacturing:

Continuous manufacturing is gaining momentum as a viable option for large-scale production of amorphous formulations. Systems integrating hot-melt extrusion with in-line monitoring tools such as near-infrared (NIR) spectroscopy ensure consistent quality during real-time production. This approach enhances product uniformity, reduces waste, and aligns with regulatory initiatives promoting process analytical technology (PAT). Continuous manufacturing is especially beneficial for scale-up of ASDs and is expected to transform how amorphous drugs are produced at the industrial level.

9. CONCLUSION:

Amorphous drug delivery systems have become an effective way to solve the ongoing problem of poor water solubility in many modern drugs. By converting drugs from their stable crystalline form into a more disordered and high-energy state, it's possible to boost how quickly they dissolve and how well they're absorbed by the body especially in drugs that fall under BCS Class II and IV. Different formulation strategies, such as amorphous solid dispersions, co-amorphous systems, and advanced techniques like spray drying or hot-melt extrusion, help keep these unstable forms stable and improve drug release.To make sure the amorphous form has been achieved and maintained, scientists rely on various testing methods like XRPD, DSC, FTIR, and in vitro dissolution studies. Still, keeping these formulations stable over time is not easy. Issues like moisture absorption, a tendency to recrystallize, and chemical breakdown can all affect product quality. This makes it important to carefully choose excipients, design stable processes, and control storage conditions.

On top of that, regulatory guidelines for amorphous drugs have become more demanding. Developers now need solid analytical data, stability studies, and quality-by-design (QbD) approaches to meet expectations. Moving from lab-scale to full-scale manufacturing can also be difficult due to challenges with consistency, cost, and production methods. However, exciting progress is being made such as using machine learning for better formulation design, exploring new types of polymers, and adopting continuous manufacturing techniques.

10. REFERENCES:

1. Markad MH, Mankar SD. Review on: Solubility enhancement of poorly water-soluble drugs. Asian J Res Pharm Sci. 2022; 12(3): 231-7.

2. Seftian M, Laksitorini MD, Sulaiman TNS. Enhancement of valsartan solubility by amorphous solid dispersion ternary system: an optimization and characterization. Res J Pharm Technol. 2024; 17(8): 3717-23.

3. Jadhav YL, Parashar B, Ostwal PP, Jain MS. Solid dispersion: solubility enhancement for poorly water-soluble drug. Res J Pharm Technol. 2012; 5(2): 190-6.

4. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002; 231(2): 131-43.

5. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48(1): 27-42.

6. Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008; 97(4): 1329-48.

7. Bhairav BA, Bachhav JK, Saudagar RB. Review on solubility enhancement techniques. Asian J Pharm Res. 2016; 6(3): 147-52.

8. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000; 17(4):397-403.

9. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3): 413-20.

10. Löbmann K, Strachan CJ. The use of co-amorphous systems to improve the performance of poorly water-soluble drugs. Int J Pharm. 2020; 589: 119912.

11. Seftian M, Laksitorini MD, Sulaiman TNS. Enhancement of valsartan solubility by amorphous solid dispersion ternary system: an optimization and characterization. Res J Pharm Technol. 2024; 17(8): 3717-23.

12. Markad MH, Mankar SD. Review on: Solubility enhancement of poorly water-soluble drugs. Asian J Res Pharm Sci. 2022; 12(3): 231-7.

13. Chavan RB, Thipparaboina R, Kumar D, Shastri NR. Co-amorphous systems: a product development perspective. Int J Pharm. 2016; 515(1-2): 403-14.

14. Dengale SJ, Grohganz H, Rades T, Löbmann K. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 2016; 100: 116-24.

15. Liu C, Desai KG, Chen X, Park H. Mechanochemical preparation and characterization of amorphous pharmaceuticals: an overview. Drug Dev Ind Pharm. 2020; 46(5): 759-67.

16. York P. Strategies for particle design using supercritical fluid technologies. Pharm Sci Technol Today. 1999; 2(11): 430-40.

17. Katta N, Narala S, Kallakunta VR, Jablonski MM, Boddu SHS, Mitra AK. Nano-amorphous formulations: a promising strategy for improving oral bioavailability of poorly soluble drugs. Pharmaceutics. 2020; 12(10): 885.

18. Lee SL, O'Connor TF, Yang X, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015; 10(3): 191-8.

19. Newman A, Engers D, Bates S, Ivanisevic I, Kelly RC, Zografi G. Characterization of amorphous API: polymer mixtures using X-ray powder diffraction. J Pharm Sci. 2008; 97(11): 4840-55.

20. Ahmad W, Sheikh R, Ahmad R, Khan S. Methods for improving the solubility of water-insoluble drugs: a comprehensive review. Res J Pharm Dosage Forms Technol. 2022; 14(4): 309-14.

21. Kapourani A, Valkanioti V, Kontogiannopoulos KN, Barmpalexis P. Determination of the physical state of a drug in amorphous solid dispersions using artificial neural networks and ATR-FTIR spectroscopy. Int J Pharm X. 2020; 2: 100063.

22. Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci. 2006; 95(8): 1641-64.

23. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997; 86(1): 1-12.

24. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48(1): 27-42.

25. Jadhav SP, Ahire SM, Shewale VV, Patil CD, Pagar RY, Sonawane DD, Mahajan SK. Formulation of tablet of nifedipine co-crystal for enhancement of solubility and other physical properties. Biosci Biotechnol Res Asia. 2025; 22(1): 191-200.

26. Dharani S, Mohamed EM, Khuroo T, Rahman Z, Khan MA. Formulation characterization and pharmacokinetic evaluation of amorphous solid dispersions of dasatinib. Pharmaceutics. 2022; 14(11): 2450.

Received on 16.07.2025 Revised on 20.08.2025

Accepted on 19.09.2025 Published on 18.10.2025

Available online from November 03, 2025

Res. J. Pharma. Dosage Forms and Tech.2025; 17(4):293-301.

DOI: 10.52711/0975-4377.2025.00041

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.